GERN: Geron to Present at the 17th Annual BIO CEO & Investor Conference

MENLO PARK, Calif., February 2, 2015 – Geron Corporation (Nasdaq:GERN) today announced that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company at the 17th Annual BIO CEO & Investor Conference in New York. The presentation is scheduled to occur on Monday, February 9, at 2:00 p.m. Eastern Time. A live webcast of the presentation will be available through the Investor Relations pages of Geron’s website or at Following the live presentation, the webcast will be archived and available for replay at the same address for a period of 30 days. About Geron Geron is a clinical… Read more »

Shares of Geron closed last Friday at $3.18 . GERN has a 1-year high of $5.28 and a 1-year low of $1.39. The stock’s 50-day moving average is $3.21 and it’s 200-day moving average is $2.69.

On the ratings front, Geron (NASDAQ:GERN) has been the subject of a number of recent research reports. In a report issued on November 14, Piper Jaffray analyst Charles Duncan upgraded GERN to Buy, with a price target of $5, which reflects a potential upside of 57.2% from last closing price. Separately, on the same day, MLV & Co.’s George Zavoico maintained a Buy rating on the stock and has a price target of $4.25.

Geron Corp is a clinical stage biopharmaceutical company engaged in the discovery and development of therapeutic products for oncology such as telomerase inhibitor, imetelstat and in hematologic myeloid malignancies, among others.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts